Titlebook: Immunotherapy for Head and Neck Cancer; Anthony T. C. Chan,Brigette B.Y. Ma Book 2023 The Editor(s) (if applicable) and The Author(s), und

Perforation

書(shū)目名稱Immunotherapy for Head and Neck Cancer影響因子(影響力)




書(shū)目名稱Immunotherapy for Head and Neck Cancer影響因子(影響力)學(xué)科排名




書(shū)目名稱Immunotherapy for Head and Neck Cancer網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Immunotherapy for Head and Neck Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Immunotherapy for Head and Neck Cancer被引頻次




書(shū)目名稱Immunotherapy for Head and Neck Cancer被引頻次學(xué)科排名




書(shū)目名稱Immunotherapy for Head and Neck Cancer年度引用




書(shū)目名稱Immunotherapy for Head and Neck Cancer年度引用學(xué)科排名




書(shū)目名稱Immunotherapy for Head and Neck Cancer讀者反饋




書(shū)目名稱Immunotherapy for Head and Neck Cancer讀者反饋學(xué)科排名

Esophagus

Anthony T. C. Chan,Brigette B.Y. MaCrosses disciplines to provide peer reviewed chapters on a multi-disciplinary theme.Updates the field by comprehensively covering head and neck cancers.Presents novel therapeutics for immunotherapy in

光亮

Cancer Immunotherapyhttp://image.papertrans.cn/i/image/462302.jpg

和平主義

978-3-031-29225-5The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl

傾聽(tīng)

混合物

閑逛

Immunological Landscape of Head and Neck Cancer: Mechanisms of Immune Escape and the Tumor Microenv within the tumor microenvironment. Although dysfunctional antitumor immunity is particularly prominent in human papillomavirus (HPV)-negative head and neck cancers, HPV-driven tumors have also developed distinct mechanisms of immune escape.

spondylosis

glucagon

Immunotherapy in Recurrent and Metastatic Nasopharyngeal Carcinoma, antibody is combined with platinum-based chemotherapy in the first-line treatment of R/M NPC have positioned immunotherapy as one of the mainstream therapeutic options for NPC. This review focused on the clinical impact of anti-PD1 antibodies on the palliative management of NPC.

悲痛

Translational and Clinical Approach to Combining Immunotherapy with Radiotherapy in the Treatment o immunotherapy to achieve optimal effect. We will review the mechanisms of immune evasion and resistance in head and neck squamous cell carcinoma, current preclinical evidence supporting the combination of radiation therapy with immunotherapy, and existing clinical data to elucidate those aforementioned questions.